Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Michel, Christian; Burchert, Andreas; Hochhaus, Andreas; Saussele, Susanne; Neubauer, Andreas; Lauseker, Michael; Krause, Stefan W; Kolb, Hans-Jochem; Hossfeld, Dieter Kurt; Nerl, Christoph; Baerlocher, Gabriela M.; Heim, Dominik; Brümmendorf, Tim H; Fabarius, Alice; Haferlach, Claudia; Schlegelberger, Brigitte; Balleisen, Leopold; Goebeler, Maria-Elisabeth; Hänel, Mathias; Ho, Anthony; ... (2018). Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. (In Press). Haematologica - the hematology journal Ferrata-Storti Foundation 10.3324/haematol.2018.206797

[img] Text
haematol.2018.206797.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800mg (high-dose) imatinib accelerated achievement of a deep molecular remission. However, whether and when a de-escalation of the dose intensity under high-dose imatinib can be safely performed without increasing the risk of losing deep molecular response is unknown. To gain insights into this clinically relevant question, we analyzed the outcome of imatinib dose reductions from 800mg to 400mg daily in the Chronic Myeloid Leukemia-Study IV. Of the 422 patients that were randomized to the 800mg arm, 68 reduced imatinib to 400mg after they had achieved at least a stable major molecular response. 61 of these 68 patients (90%) maintained major molecular remission on imatinib at 400mg. Five of the seven patients, who lost major molecular remission on the imatinib standard dose, regained major molecular remission while still on 400mg imatinib. Only two of 68 patients had to switch to more potent kinase inhibition to regain major molecular remission. Importantly, the lengths of the imatinib high-dose treatment intervals before and after achieving major molecular remission were associated with the probabilities of maintaining major molecular remission with the standard dose of imatinib. Together, data support that a deep molecular remission achieved with high-dose imatinib, can be safely maintained with standard dose in most patients. The study protocol was registered at ClinicalTrials.gov (NCT00055874).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)

UniBE Contributor:

Baerlocher, Gabriela M.

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0390-6078

Publisher:

Ferrata-Storti Foundation

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

08 Jan 2019 12:56

Last Modified:

08 Jan 2019 12:56

Publisher DOI:

10.3324/haematol.2018.206797

PubMed ID:

30514803

Uncontrolled Keywords:

CML study IV Chronic Myelogenous Leukemia dose reduction imatinib safety

BORIS DOI:

10.7892/boris.123262

URI:

https://boris.unibe.ch/id/eprint/123262

Actions (login required)

Edit item Edit item
Provide Feedback